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Oral Apolipoprotein A-I Mimetic D-4F Lowers
HDL-Inflammatory Index in High-Risk Patients:
A First-in-Human Multiple-Dose, Randomized
Controlled Trial
Richard L. Dunbar1,2,3,4,∗ , Rajesh Movva5 , LeAnne T. Bloedon6 , Danielle Duffy7 , Robert B. Norris2 , Mohamad Navab8 ,
Alan M. Fogelman8 and Daniel J. Rader1,2,3,4

A single dose of the apolipoprotein (apo)A-I mimetic peptide D-4F rendered high-density lipoprotein (HDL) less inflammatory,
motivating the first multiple-dose study. We aimed to assess safety/tolerability, pharmacokinetics, and pharmacodynamics of
daily, orally administered D-4F. High-risk coronary heart disease (CHD) subjects added double-blinded placebo or D-4F to statin
for 13 days, randomly assigned 1:3 to ascending cohorts of 100, 300, then 500 mg (n = 62; 46 men/16 women). D-4F was
safe and well-tolerated. Mean ± SD plasma D-4F area under the curve (AUC, 0–8h) was 6.9 ± 5.7 ng/mL*h (100 mg), 22.7 ±
19.6 ng/mL*h (300 mg), and 104.0 ± 60.9 ng/mL*h (500 mg) among men, higher among women. Whereas placebo dropped
HDL inflammatory index (HII) 28% 8 h postdose (range, 1.25–0.86), 300–500 mg D-4F effectively halved HII: 1.35–0.57 and 1.22–
0.63, respectively (P < 0.03 vs. placebo). Oral D-4F peptide dose predicted HII suppression, whereas plasma D-4F exposure was
dissociated, suggesting plasma penetration is unnecessary. In conclusion, oral D-4F dosing rendered HDL less inflammatory,
affirming oral D-4F as a potential therapy to improve HDL function.
Clin Transl Sci (2017) 10, 455–469; doi:10.1111/cts.12487; published online on 9 August 2017.

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Single-dose apoA-I mimetic peptide D-4F rendered HDL
less inflammatory. Orally available peptides are preferable,
avoiding injections.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ Whether chronic oral D-4F would safely and durably
improve HDL HII following typical dose-responsive plasma
pharmacokinetics.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ Oral D-4F stably improved HII additively to statin therapy; counter-intuitively, improvement was strongly related
to oral dosing as opposed to plasma exposure, now provid-

High-density lipoprotein cholesterol (HDL-C) is inversely
related to coronary heart disease (CHD).1 Its major protein, apolipoprotein A-I (apoA-I), predicts CHD better,2 having proven atheroprotective by transgenic overexpression,3
somatic gene transfer,4 or intravenous infusion5 in animal

ing human data congruent with emerging preclinical studies showing intestinal apoA-I mimetic exposure alters HII
absent systemic absorption.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE
✔ Decoupling apoA-I peptides from the vagaries of systemic absorption unexpectedly opens up a wide opportunity for oral peptide dosing, reviving hope that oral peptides will improve HDL function, obviating injections, and
thereby renewing the prospects for development of apoA-I
mimetics.

models. As part of a broader effort to enhance HDL function,7
infusing the full apoA-I molecule yielded mixed results on
atherosclerosis (review by Chyu & Shah).6 Although these
efforts have not validated apoA-I as a therapy, they have not
ruled it out. The size of the apoA-I molecule itself poses a
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logistical/financial barrier to development. The difficulty synthesizing such a large molecule (243 aa) inspired smaller peptides mimicking apoA-I function.
Encouragingly, apoA-I mimetics reduced8 or regressed9
atherosclerosis in animals, altering HDL function without
changing HDL-C mass. Proposed mechanisms include
accelerating HDL-mediated cholesterol efflux/reverse
cholesterol transport and enhancing HDL’s anti-oxidant/antiinflammatory properties.10 Indeed, HDL’s anti-inflammatory
properties outperform HDL-C mass in identifying high-risk
patients.11 Moreover, injecting human apoA-I into mice rendered HDL less inflammatory, as with human volunteers.12
Statins present a clinically relevant benchmark for improving the HDL inflammatory index (HII), lowering HII 28% in
patients with CHD.11 However, this drop failed to render
high-risk patients’ HDL anti-inflammatory, motivating other
approaches to augment the partial benefit of statins.13,14 A
key property for an apoA-I mimetic is the ability to lower HII,
especially beyond statin.
D-4F is a peptide comprising 18 D-amino acids whose
tertiary structure resembles apoA-I, without sequence
homology.8 We conducted the first human studies wherein
a single oral dose of D-4F was minimally absorbed in healthy
volunteers (BP-01) and patients with CHD (BP-02). Despite
minimal plasma exposure, D-4F improved HII,15 posing a
conundrum: If so little oral D-4F reaches the circulation, how
is it suppressing HDL inflammation so profoundly? Intriguingly, this seeming disconnect is congruent with subsequent
animal studies revealing the intestine as D-4F’s site of action.
Here, we report the first multiple-dose study of oral
D-4F in man (BP-03). The primary objective was to assess
D-4F’s safety, tolerability, and pharmacokinetics among
statin-treated subjects with stable CHD or equivalent risk.
Secondarily, we assessed pharmacodynamics by HII, using
a cell-based assay, the most sensitive indicator for D-4F’s
biological activity.15
METHODS
Trial design
This was a proof-of-concept, single-center, doubleblinded/placebo-controlled parallel clinical trial of 13 daily
doses of placebo/active D-4F randomized 1:3 in three
sequential, ascending-dose cohorts: 100 mg, 300 mg, or
500 mg D-4F/placebo. Additional methodologic details
appear in Supplementary Text S1.
Participants
We recruited patients aged 21–80 years with stable CHD
or equivalent risk per adult treatment panel-III criteria, on
stable-dose statin (>4 weeks; Supplementary Table S1).
Subjects gave written informed consent. Visits took place
at the University of Pennsylvania (UPenn) General Clinical Research Center. The UPenn Institutional Review Board
approved the study, conducted per Good Clinical Practice.
Interventions
D-4F peptide was diluted in 60 mL 25% sucrose-water
as described.11 Cohorts of 20 were randomized 15 D-4F/5
placebo in 3 ascending-dose groups: 100 mg, 300 mg, and
500 mg, dosed after the overnight fast but 2 h before
Clinical and Translational Science

breakfast and concomitant medications. For example, the
first cohort (n = 20) was assigned placebo/D-4F 1:3, yielding 5 placebo/15 D-4F. When the 100 mg group nearly completed 13 days, the principal investigator (R.L.D.) reviewed
safety/tolerability before approving the next group, 300 mg.
The same randomization/review process was conducted
with the 300 mg and 500 mg groups. Seven visits included
screening and two safety visits at 21 days and 42 days.
Subjects reported on days 1, 3, 7, and 13 for supervised
dosing, and otherwise took D-4F at home. Blood samples were drawn for pharmacokinetics/pharmacodynamics
before (time 0) and 15 min, 30 min, 1 h and 2 h after the first
and last dose (days 1 and 13). Samples were obtained 2 h
postdose on days 3 and 7, extending to 8 h on day 13. The
latter provided the most extensive serial observations: 0, 2, 4,
and 8 h; accordingly, pharmacokinetics/pharmacodynamics
focus on day 13.

Outcomes
The primary outcomes were safety/tolerability and D-4F
pharmacokinetics, and secondarily pharmacodynamics: HII
by monocyte chemotactic activity (MCA).

Assays
Plasma D-4F levels were assayed as described,11 detecting 1.0 ng/mL. For HII, samples were sucrose cryopreserved and analyzed blinded to treatments as described,11
as were ancillary lipid or anti-inflammatory biomarkers based
on prior animal or human studies.10,15–19 MCA values in
the absence of HDL were normalized to one (i.e., HII is
the ratio [MCALDL+HDL ]/[MCALDL alone ], reduced to a unit ratio
(UR). Thus, 1.0 UR is neutral/normal, indicating added HDL
was neither pro-inflammatory nor anti-inflammatory, because
MCALDL+HDL = MCALDL . If added HDL were pro-inflammatory,
MCALDL+HDL >MCALDL , so HII >1.0 UR. Conversely, if added
HDL were anti-inflammatory, MCALDL+HDL <MCALDL , so HII
<1.0 UR. Based on prior studies, we did not expect ancillary
tests of lipid or anti-inflammatory biomarkers to change, but
assayed several in case multiple-daily dosing caused unanticipated emergent benefits.

STATISTICAL METHODS
Because the primary objective of this proof-of-concept
experiment was to assess safety, tolerability, and pharmacokinetics, no formal power calculations were performed. By
clinical judgment, the enrollment goal was 60 completers.
Comparative pharmacokinetic/pharmacodynamic changes
were assessed between dose groups, and within dose
groups predose/postdose, and between dose groups vs.
placebo. Gender was considered a potential interacting factor. A linear mixed model of repeated measurements tested
differences between D-4F dose groups and placebo at each
time point. Pairwise comparisons of least square means
between D-4F groups and placebo at each time point were
examined. Statistical analyses were two-tailed (α = 0.05),
and results unadjusted unless indicated.
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Pharmacokinetic and pharmacodynamic calculations
Pharmacokinetic parameters, including the area under the
curve (AUC) from 0 h to the last measurable concentration
(AUC(0–t) ), or extrapolated to infinity (AUC(0–inf) ), apparent elimination half-life, maximum concentration (Cmax ), and time of
maximum (Tmax ) concentration postdose, were computed by
noncompartmental analysis using Stata version 14. Integrating time points from 0–8 h, the resulting area is less dependent on individual time points than constraining analysis to
a particular time point. Since most subjects’ D-4F was close
to/approaching zero at 8 h, extrapolating to infinity scarcely
changed the area. Therefore, we used the actual data from 0–
8 h rather than extrapolate. A woman on 500 mg had extreme
plasma D-4F concentrations confirmed by retesting; hence,
we consider her a bona fide biological outlier, and censored
the data set by simply dropping her data. Therefore, pharmacokinetics conservatively, if grossly, underestimate D-4F
levels, especially among women. On an exploratory basis,
we used regression to evaluate the pharmacodynamic curve
between D-4F dose and censored plasma D-4F AUC over
8 h on day 13, and to evaluate the curve between D-4F dose
and primary pharmacodynamic outcome, postdose change
in HII by MCA.

RESULTS
Participants
We recruited 47 eligible men and 16 sterile women from
July to December 2005, enrolling 62 receiving 1 dose of
D-4F/placebo (46 men/16 women). Altogether, 59 subjects
completed 12 visits, mean age 60.5 years (range, 28–78
years), weight 93.5 kg, and body mass index 31.6 kg/m2
(Table 1). Enrollees taking 1 dose comprised the safety
analysis (n = 62). Pharmacokinetic/pharmacodynamic analysis was per protocol (n = 59) by the three completer
cohorts taking 12/13 daily doses of D-4F/placebo: (1) 20
completers/21 enrollees (100 mg group); (2) 20/21 (300 mg
group); and (3) 19/20 (500 mg group), totaling 59 of 62. Additional details are outlined in Supplementary Text S2.

Safety and tolerability
Vitals, safety laboratory tests, and examinations were unremarkable at all visits, as were electrocardiograms save a
placebo-exposed subject with atrial fibrillation. Altogether, 74
adverse events (AEs) affected 53%, chiefly nasopharyngitis
(11% of total events), urinary tract infections (8%), extremity
pain (7%), and myalgia (5%; Table 2). Affected subjects were
similar by group: 7 (100 mg), 9 (300 mg), and 10 (500 mg;
44–67% of subjects receiving any D-4F), and 7 on placebo
(44%). However, AE counts were dose-related: 12 (100 mg),
20 (300 mg), and 26 (500 mg), most mild to moderate (64
events). Six subjects experienced 10 AEs of severe intensity.
Only one was possibly drug-related, a subject on 500 mg
in the D-4F group with vasovagal syncope. However, none
of the severe AEs warranted medication withdrawal. There
was one serious AE requiring hospitalization: 9 days after
completing D-4F, a patient with CHD had angina following a
heated workplace dispute; investigations ruled out myocardial infarction. No other serious AEs occurred.

Pharmacokinetic results
In the 500 mg group, we censored pharmacokinetic analyses, eliminating the woman with extremely high D-4F: Cmax
640 ng/mL (vs. 49 for the other women on 500 mg), and
AUC(0–8h) 1,437 ng/mL*h (vs. 246; Supplementary Table S2
vs. Table 3). For the remaining, censored population, postdose plasma D-4F levels rose rapidly, peaking 1.3–2.4 h
across groups (Figure 1). On day 13, predose/trough D-4F
was undetectable in all the study groups (<1 ng/mL), except
two subjects on 500 mg achieving low concentrations: 1.06
and 4.41 ng/mL. Pooling genders, after 13 days, the mean
confidence interval (CI) Cmax (ng/mL) from 100 mg was 2.8
(CI = 2–3.6), from 300 mg 8.1 (CI = 5.2–11), and from 500 mg
37.1 (CI = 20.3–53.9) when D-4F was detectable postdose.
The Cmax remained relatively stable from days 1–13, as was
the AUC(0–t) from 0–2 h postdose (Table 3). The D-4F levels 2 h postdose peaked at 3–7 days, and did not increase
thereafter. Plasma D-4F AUC increased from 100 mg to
500 mg (P < 0.0001 by nonparametric test for trend).
Typically, women achieved higher plasma levels than men
(Figure 1a,b). Unsurprisingly, women had higher effective
doses on adjusting nominal dose for body size. Ideal body
mass (IBM)20 was particularly informative, women having
higher D-4F/IBM than men (Supplementary Figure S2).
Affirming the nonparametric test, we used regression
to model the dose/response curve, allowing us to gauge
whether other factors might influence the dose/response
relationship, particularly gender. Often, plasma D-4F was
undetectable, resulting in a large number of zero values in
the dependent variable, motiving two-part regression,21 consisting of (1) logistic regression modeling presence/absence
of detectable D-4F, and (2) generalized linear modeling conditional on D-4F detection. The dose/response curve was
greater than linear (i.e., higher doses prompted greater
plasma D-4F exposure than rectilinear projections based
on the increase in dose). Accordingly, the generalized linear modeling residuals had a log-normal right skew, so an
exponential function provided the best fit (Supplementary
Table S3).
Although the nominal D-4F dose predicted plasma D-4F
exposure (overall R2 = 0.64/P < 0.0001), a much better
fit was achieved by adjusting D-4F dose by body weight,
henceforth, the effective dose. Specifically, IBM achieved
the best fit (R2 = 0.78/P < 0.0001; Figure 1c and Supplementary Table S3); moreover, relative likelihood suggested the model based on nominal D-4F dose was only
50% as informative as D-4F/IBM. Regardless of how the
D-4F dose was modeled (nominal vs. effective dose), there
was a strong dose/response relationship between D-4F
dose and (1) absence/presence of detectable plasma D4F, and (2) plasma D-4F AUC (all P < 0.0001). Hence, with
greater D-4F doses, D-4F was more likely detected, and
among those achieving detectable levels, the plasma D-4F
AUCs increased more than dose-proportional with increasing doses.
Neither the discrete nor continuous aspects of the
dose/response relationship were influenced by gender. This
suggests greater plasma D-4F exposure among women follows their higher effective D-4F doses.

www.cts-journal.com
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Table 1 Baseline characteristics
Characteristic

Placebo

100 mg

300 mg

500 mg

Pooled

Disposition and analytical population
Total enrolled: safety population

16

16

15

15

Withdrew before 12/13 visits

1 (6%)

1 (6%)

0 (0%)

1 (7%)

3 (5%)

15 (94%)

15 (94%)

15 (100%)

14 (93%)

59 (95%)

Completed 12/13 visits:
unabbridged efficacy population

62

Severe outlier on plasma D-4F PKs

0 (0%)

0 (0%)

0 (0%)

1 (7%)

1 (2%)

PK outlier Dropped: Censored PKs
population

15 (94%)

15 (94%)

15 (100%)

13 (87%)

58 (94%)

14 (88%)

12 (75%)

9 (60%)

11 (73%)

46 (74%)

2 (13%)

4 (25%)

6 (40%)

4 (27%)

Demographics
Men
Women, uncensored
Age, years

61.0 (11.8)

59.2 (9.5)

59.9 (8.4)

62.0 (8.0)

16 (26%)
60.5 (9.4)

Race/ethnicity (nonexclusive categories)
Native American

1 (6%)

0 (0%)

0 (0%)

0 (0%)

1 (2%)

African American

2 (13%)

3 (19%)

5 (33%)

1 (7%)

11 (18%)
49 (79%)

White

12 (75%)

13 (81%)

10 (67%)

14 (93%)

Multiracial

1 (6%)

0 (0%)

0 (0%)

0 (0%)

1 (2%)

Hispanic

1 (6%)

0 (0%)

1 (7%)

0 (0%)

2 (3%)

Men

174.3 (4.9)

176.8 (7.3)

176.1 (7.1)

178.1 (5.9)

176.2 (6.2)

Women

159.5 (7.8)

157.1 (6.0)

164.6 (4.1)

156.0 (7.0)

159.9 (6.5)

Anthropometrics
Height, cma
Total body mass, kg
IBM, kga
Lean body mass, kga
Body surface area, m2b

94.7 (15.5)

96.7 (16.1)

92.2 (19.7)

92.4 (20.2)

94.0 (17.6)

Men

69.8 (4.4)

72.1 (6.7)

71.5 (6.4)

73.2 (5.3)

71.5 (5.6)

Women

51.9 (7.0)

49.8 (5.5)

56.5 (3.7)

48.7 (6.4)

52.3 (5.9)

Men

66.8 (6.8)

69.1 (7.6)

65.4 (9.0)

67.4 (8.9)

67.3 (7.8)

Women

47.0 (3.4)

47.1 (5.2)

52.7 (7.4)

46.2 (7.0)

49.0 (6.6)

Men

1.98 (0.16)

2.05 (0.20)

1.97 (0.22)

2.02 (0.20)

2.00 (0.19)

Women
Body mass index, kg/m2

1.74 (0.08)

1.76 (0.17)

1.92 (0.27)

1.73 (0.24)

1.81 (0.22)

31.8 (4.2)

32.6 (3.8)

31.2 (5.9)

31.2 (6.2)

31.7 (5.0)

Major sources of risk (nonexclusive categories)
CHD

11 (69%)

6 (38%)

8 (53%)

10 (67%)

35 (56%)

DM

8 (50%)

11 (69%)

8 (53%)

7 (47%)

34 (55%)

Other ASCVD (e.g., PAD, AAA, CVD)

0 (0%)

1 (6%)

0 (0%)

0 (0%)

1 (2%)

FRS >20% absent CHD, ASCVD, or
DM

1 (6%)

0 (0%)

0 (0%)

1 (7%)

2 (3%)

CHD and DM

3 (19%)

1 (6%)

1 (7%)

2 (13%)

7 (11%)

CHD absent other ASCVD and DM

7 (44%)

4 (25%)

8 (53%)

7 (47%)

26 (42%)

12 (75%)

13 (81%)

9 (60%)

10 (67%)

44 (71%)

Hypertension
HDLs
HDL-C, mg/dLc
ApoA-I, mg/dLa
Predose HDL inflammatory index,
UR

Men

41.3 (7.4)

45.3 (12.0)

42.4 (11.8)

42.2 (7.8)

Women

76.0 (17.0)

48.3 (12.8)

54.0 (12.8)

58.8 (14.4)

42.8 (9.6)
56.5 (14.9)

Men

109.6 (14.2)

113.5 (16.5)

104.9 (15.4)

115.7 (11.1)

111.2 (14.5)

Women

148.5 (16.3)

124.0 (16.3)

120.3 (10.4)

140.3 (14.1)

131.9 (16.7)

1.25 (0.36)

1.21 (0.36)

1.35 (0.46)

1.22 (0.22)

1.26 (0.36)

Atherogenic lipoproteins
Non-HDL-C, mg/dL

102.1 (28.8)

107.6 (32.9)

112.7 (34.1)

99.5 (23.5)

105.5 (29.8)

Apo B100, mg/dL

72.2 (18.3)

74.1 (18.7)

77.4 (22.7)

69.7 (12.3)

73.2 (17.9)

TG, mg/dL, median, PSD

143 (86.3)

127 (54.8)

99 (66.7)

92 (71.1)

110 (71.9)

VLDL-C, mg/dL

25.0 (16.4)

23.3 (12.8)

20.6 (12.7)

25.7 (19.7)

23.6 (15.4)

LDL-C UC, mg/dL

77.1 (24.9)

84.4 (27.8)

92.1 (35.8)

73.9 (18.6)

81.8 (27.7)

AAA, abdominal aortic aneurysm; Apo, apolipoprotein; ASCVD, atherosclerotic cardiovascular disease; CHD, coronary heart disease; CVD, cardiovascular disease;
DM, diabetes mellitus; FRS, Framingham risk score; HDL, high-density lipoprotein; HDL-C, high-density lipoprotein-cholesterol; IBM, ideal body mass; PAD,
peripheral artery disease; PK, pharmacokinetic; PSD, pseudo-SD; TG, triglyceride; UC, by ultracentrifugation; UR, unit rate; VLDL-C, very low-density lipoproteincholesterol.
Unless otherwise stated, continuous data are presented as mean (SD). Skewed data are presented as median (pseudo-SD [PSD]). Significance test for interaction
by gender: ± <0.1, a P < 0.05, b P < 0.01, c P < 0.001, a P < 0.0001.
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Table 2 Adverse events by dose group and intensity
Dose
No. of subjects with AEs

Mild

Moderate

Severe

Total

28 (100%)

9 (100%)

6 (100%)

33 (100%)

Cardiac disorders
Angina pectoris

300 mg

1 (3.6%)

0 (0)

1 (16.7%)

2 (6.1%)

Atrial fibrillation

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Eye disorders
Arcus lipoids

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Vision blurred

300 mg

0 (0)

0 (0)

1 (16.7%)

1 (3.0%)

Abdominal distension

300 mg

2 (7.1%)

0 (0)

0 (0)

2 (6.1%)

Abdominal pain upper

100 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)
1 (3.0%)

Gastrointestinal disorders

500 mg

0 (0)

1 (11.1%)

0 (0)

Diarrhea

100 mg

2 (7.1%)

0 (0)

0 (0)

2 (6.1%)

Dry mouth

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Dyspepsia

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

100 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Flatulence

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Gastric disorder

500 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Gastro-esophageal
reflux disease

500 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Hematochezia

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Nausea

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

500 mg

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

100 mg

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

Toothache

General disorders and administration site conditions
Chest pain

Placebo

0 (0)

2 (22.2%)

0 (0)

2 (6.1%)

300 mg

0 (0)

0 (0)

1 (16.7%)

1 (3.0%)

Fatigue

500 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Edema

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Pain

Placebo

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

500 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

500 mg

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

Immune system disorders
Hypersensitivity
Infections and infestations
Ear infection

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Influenza

100 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Nasopharyngitis

100 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)
5 (15.2%)

Urinary tract infection

500 mg

5 (17.9%)

0 (0)

0 (0)

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

100 mg

2 (7.1%)

0 (0)

0 (0)

2 (6.1%)

300 mg

2 (7.1%)

0 (0)

0 (0)

2 (6.1%)

500 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Injury, poisoning, and procedural complications
Animal bite

500 mg

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

Contusion

500 mg

0 (0)

0 (0)

1 (16.7%)

1 (3.0%)

Limb injury

500 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

100 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Investigations
Cardiac murmur

Musculoskeletal and connective tissue disorders
Arthralgia

Placebo

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Back pain

300 mg

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

500 mg

0 (0)

0 (0)

1 (16.7%)

1 (3.0%)
(Continued)
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Table 2 Continued
Dose

Mild
0 (0)

Moderate
1 (11.1%)

Severe
0 (0)

Total

Chest wall pain

Placebo

1 (3.0%)

Muscle spasms

Placebo

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Musculoskeletal pain

500 mg

0 (0)

0 (0)

1 (16.7%)

1 (3.0%)

Myalgia

Placebo

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

500 mg

1 (3.6%)

1 (11.1%)

0 (0)

2 (6.1%)

300 mg

1 (3.6%)

0 (0)

2 (33.3%)

3 (9.1%)

500 mg

2 (7.1%)

0 (0)

0 (0)

2 (6.1%)

Placebo

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

Headache

100 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Syncope vasovagal

500 mg

0 (0)

0 (0)

1 (16.7%)

1 (3.0%)

Pain in extremity
Shoulder pain
Nervous system disorders

Respiratory, thoracic, and mediastinal disorders
Rhinorrhea

100 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Throat irritation

300 mg

1 (3.6%)

0 (0)

0 (0)

1 (3.0%)

Placebo

0 (0)

1 (11.1%)

0 (0)

1 (3.0%)

Skin and subcutaneous tissue disorders
Pruritus
AEs, adverse events.

Pharmacodynamic results
Acute-on-chronic dosing lowers HDL inflammatory index
Following 13 days of D-4F, predose baseline HII ranged from
1.2–1.4 UR across groups, confirming our high-risk subjects
started out with pro-inflammatory HDL, this despite statin
therapy. In all groups, HII fell 2 h postdose. For example,
in those assigned placebo, HII was 1.25 UR predose, then
reached to 0.82 UR by 2 h (–31%; P = 0.0001 vs. predose; Table 4). The drop ranged from –15.8% (100 mg) to
–40.5% (500 mg). We can only speculate to what study procedure caused a universal drop in HII 2 h postdose. This
could reflect diurnal changes, prolonged fasting, or enforced
bed rest. Greater drops accompanied 300 mg and 500 mg
2, 4, and 8 h postdose vs. 100 mg (P < 0.05; Table 4 and
Figure 2a). More importantly, higher doses differed from
placebo. Notably, HII fell more on 300 mg vs. placebo 4–8 h
postdose and 8 h postdose on 500 mg (all P < 0.05). At best,
by 8 h 300 mg dropped HII from 1.35 to 0.57 UR (–57.8%) and
500 mg 1.22–0.63 UR (–48.4%); thus, despite different baselines, at higher D-4F doses, HII settled to a very similar level:
0.60 UR vs. 0.86 UR for placebo. At best, 300 and 500 mg D4F approximately halved HII vs. 30% less on placebo; thus,
placebo-corrected suppression was –27% beyond placebo
for 300 mg (P < 0.005 vs. placebo) and –21% for 500 mg (P
< 0.03). Placebo correction simply subtracts the %change in
the placebo group from the gross %change in a given active
D-4F group. This net change reflects the added contribution
of D-4F. For 4 h and 8 h, the “placebo-corrected” change
is somewhat a misnomer, because patients took their usual
medications at 2 h with breakfast. Importantly, this included
their morning regimen to prevent atherosclerotic cardiovascular disease (ASCVD). Thus, the net contribution of D-4F is
the added contribution of D-4F beyond any benefits of subjects’ ASCVD medications. This is an important distinction,
as the goal of development is to improve HII beyond any benefits of usual clinical care to prevent ASCVD. On the lowest D4F dose, 100 mg, the drop in HII was indistinguishable from
that of placebo, except at 4 h, when HII fell less than placebo
Clinical and Translational Science

(P = 0.04). This suggests 300 mg D-4F is required to suppress HII to around 0.60 UR.
Indeed, a dose/response relationship between D-4F and
HII was apparent, as D-4F dose inversely related to HII (P =
0.0018 by nonparametric trend test). There was a mild but
significant inverse correlation between D-4F AUC and HII
%change 8 h postdose (r = –0.38/P = 0.0360), and D4-F
incremental area under the curve (incAUC) and HII incAUC
negatively correlated (Spearman’s rho = –0.37/P = 0.01).
Similarly, there was a modest trend for nominal D-4F dose
to predict lower HII incAUC, as higher D-4F doses predicted enhanced HII suppression (rho = –0.32/P = 0.01;
Figure 2b). These nonparametric tests suggest greater D-4F
doses, and, to some extent, plasma D-4F exposure portends
lower/improved HII.
We then modeled the dose/response curve between D4F and HII. As effective dose rose (D-4F mg/kg IBM),
HII fell linearly. However, upon reaching an effective dose
of 3.5 mg/IBM, the curve flattened to a floor (Figure 2c
and Supplementary Table S4, model 4, R2 = 0.32/P =
0.0004). Importantly, individuals dosed 3.5 mg/IBM had a
lower HII compared to placebo (P = 0.03), whereas dosing
<3.5 mg/IBM was statistically no worse than the diurnal drop
from placebo (P = 0.06). As a practical matter, all subjects on
100 mg received <3.5 mg/IBM. Accounting for variability, the
90%/95% tolerance interval (TI) provides a range that 90% of
the underlying population should fall within, at 95% CI. The TI
provides a “reality check” on whether a particular dose might
bring the overwhelming majority (90%) of subjects to a goal.
For D-4F, a dose achieving a lower TI boundary >3.5 mg/IBM
would assure the vast majority of subjects were “on the
floor” of the dose/response curve. On 300 mg, effective dose
ranged 3.6–6.1 mg/IBM, averaging 4.7. Although all were
dosed to 3.5 mg/IBM, the TI ranged 2.9–6.5 mg/IBM. Thus,
in a larger study, 300 mg will probably fall short. Likewise, all
on 500 mg received 3.5 mg/IBM (range, 6.2–11.9 mg/IBM),
but TI ranged 2.8–12.9 mg/IBM. Accordingly, if 300 or 500 mg
were set as fixed doses, their corresponding TIs suggest not
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Table 3 Pharmacokinetics of D-4F in plasma
Characteristic

100 mg

300 mg

500 mg uncensored

500 mg after censoring
women

I. Pharmacokinetics including subjects with undetectable plasma D-4F treated as zero values
A. Plasma D-4F Cmax , where Cmax = 0 when D-4F undetectable, ng/mL, mean (95% CI)
Day 1 (0–2 h)

Men

2.37 (1.31–3.43)

4.43 (1.17–7.69)

Women

4.03 (-2.55 to 10.61)

6.86 (3.70–10.02)

177.98 (-43.36 to 399.32)

67.30 (5.05–129.55)

Pooled across interactiona

[2.70 (1.27–4.14)]

[5.40 (3.07–7.74)]

[64.61 (-0.46 to 129.68)]

[32.80 (12.80–52.79)]

Day 13 (0–8 h)

Men

2.27 (1.31–3.23)

5.38 (2.54–8.21)

33.56 (14.81–52.30)

Women

2.25 (-0.15 to 4.65)

Pooled across interactionb

2.27 (1.40–3.13)

23.39 (6.32–40.45)

23.39 (6.32–40.45)

33.56 (14.81–52.30)

10.80 (5.83–15.77)

196.80 (-94.21 to 487.80)

49.06 (7.98–90.15)

7.55 (4.68–10.41)

80.20 (-5.62 to 166.01)

37.14 (20.36–53.91)

B. Plasma D-4F AUC, where AUC = 0 when D-4F undetectable, ng/mL × hour, mean (95% CI)
Day 1 (0–2 h)

Men

2.82 (1.05–4.60)

4.56 (1.57–7.54)

Women

6.42 (-4.15 to 16.98)

7.00 (3.79–10.21)

32.94 (7.82–58.07)
246.59 (-37.00 to 530.18)

32.94 (7.82–58.07)
107.66 (-4.40 to 219.73)

Pooled across interactiona

[3.54 (1.14–5.93)]

[5.53 (3.31–7.75)]

[89.92 (4.03–175.80)]

[48.95 (16.19–81.72)]

Day 13 (0–8 h)

6.94 (3.70–10.18)

22.70 (9.85–35.54)

104.06 (66.41–141.71)

104.06 (66.41–141.71)

Men
Women

Pooled across interactiona

11.60 (-2.82 to 26.02)

47.37 (27.06–67.68)

522.93 (-39.03 to 1084.89)

246.76 (33.16–460.36)

[7.87 (4.20–11.55)]

[32.57 (20.09–45.04)]

[223.74 (44.56–402.91)]

[136.99 (75.92–198.06)]

II. Pharmacokinetics excluding subjects with undetectable plasma D-4F
A. Excluded population: D-4F-exposed subjects with undetectable plasma D-4F (day 1 5/45 = 11%, day 13 4/44 = 9%)
Day 1 (0–2 h)

3/15 (20%)

2/15 (13%)

0/15 (0%)

Day 13 (0–8 h)

3/15 (20%)

1/15 (7%)

0/14 (0%)

B. Plasma D-4F time of events when D-4F detected on day 13, pooling genders, hours, mean (95% CI)
Time of peak
T-Half

Mean (CI)

2.25 (1.61–2.89)

2.39 (1.47–3.31)

1.65 (0.89–2.42)

Median (range)

2.00 (1.00–4.00)

2.00 (0.50–7.92)

1.27 (0.25–4.02)

Mean (CI)

0.81 (0.29–1.32)

1.18 (0.60–1.77)

1.99 (1.38–2.60)

Median (range)

0.46 (0.37–3.04)

0.45 (0.33–2.95)

1.88 (0.35–4.83)

C. Plasma D-4F Cmax when D-4F detected, ng/mL, mean (95% CI)
Day 1 (0–2 h)

Men

2.84 (1.81–3.88)

5.70 (2.01–9.38)

Women

6.05 (-3.06 to 15.16)

6.86 (3.70–10.02)

177.98 (-43.36 to 399.32)

67.30 (5.05–129.55)

Pooled across interactiona

[3.38 (1.80–4.95)]

[6.23 (3.85–8.62)]

[64.61 (-0.46 to 129.68)]

[32.80 (12.80–52.79)]

Day 13 (0–8 h)

Men

2.72 (1.82–3.63)

6.05 (3.20–8.89)

33.56 (14.81–52.30)

Women

3.37 (1.72–5.03)

10.80 (5.83–15.77)

196.80 (-94.21 to 487.80)

49.06 (7.98–90.15)

2.83 (2.04–3.62)

8.09 (5.22–10.95)

80.20 (-5.62 to 166.01)

37.14 (20.36–53.91)

Pooled across interactionb

23.39 (6.32–40.45)

23.39 (6.32–40.45)

33.56 (14.81–52.30)

D. Plasma D-4F observed AUC when D-4F detected, ng/mL × hour, mean (95% CI)
Day 1 (0–2 h)

Men

3.38 (1.43–5.34)

5.86 (2.63–9.09)

Women

9.62 (-5.08 to 24.33)

7.00 (3.79–10.21)

32.94 (7.82–58.07)
246.59 (-37.00 to 530.18)

32.94 (7.82–58.07)
107.66 (-4.40 to 219.73)

Pooled across interactiona

[4.42 (1.64–7.21)]

[6.38 (4.17–8.59)]

[89.92 (4.03–175.80)]

[48.95 (16.19–81.72)]

Day 13 (0–8 h)

8.33 (5.09–11.56)

25.54 (12.41–38.67)

104.06 (66.41–141.71)

104.06 (66.41–141.71)

Men
Women

Pooled across interactiona

17.40 (2.03–32.76)

47.37 (27.06–67.68)

522.93 (-39.03 to 1084.89)

246.76 (33.16–460.36)

[9.84 (6.00–13.68)]

[34.89 (22.42–47.36)]

[223.74 (44.56–402.91)]

[136.99 (75.92–198.06)]

E. Plasma D-4F extrapolated AUC when D-4F detected on day 13, ng/mL × hour, mean (95% CI)
Day 13 (0–)

Men
Women

Pooled across interactiona

27.24 (12.83–41.66)

111.07 (71.91–150.22)

111.07 (71.91–150.22)

19.94 (-0.40 to 40.28)

8.47 (4.87–12.08)

50.21 (28.84–71.59)

574.85 (12.12–1137.59)

304.27 (38.08–570.47)

[10.56 (5.71–15.41)]

[38.73 (24.69–52.77)]

[243.58 (57.54–429.61)]

[155.65 (79.95–231.36)]

AUC, area under the curve; CI, confidence interval; Cmax , peak plasma concentration.
Italics indicate a mean that was arrived at by dropping observations from a woman with an extraordinarily robust plasma response to D-4F, who was considered
a biological outlier. Censored means thereby conservatively err on the side of underestimating the effect of D-4F, especially among women. Significance test for
interaction by gender (a.k.a. effect modification): a P < 0.05; b P < 0.1. When interaction is present, the pooled results should be treated with special caution, as
results may not be readily generalized to mixed-gender populations, unless they match the ratio of men to women within the particular group being generalized.
Some authorities suggest accepting P < 0.1 as evidence for significant interaction. Pooled results affected by significant effect modification at P < 0.05 are
enclosed by brackets. Parameters incorporating time were based on actual times rather than target times.

all would receive 3.5 mg/IBM. Thus, higher fixed doses may
be needed to maximally suppress HII.
This analysis also suggested that gender does not influence the dose/response, either by (1) shifting the entire curve
up/down the y-axis (P = 0.5 for intercept) or (2) altering the

shape of the curve (P = 0.6 for effect modification). Hence,
the effective dose in mg D-4F/IBM adequately incorporates
the apparent gender interaction, probably because IBM itself
is gender-dependent. If affirmed, more consistent results
might be obtained by dosing D-4F by IBM in mechanistic
www.cts-journal.com
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Figure 1 (a) The time course of plasma D-4F is presented for subjects with detectable levels over 8 h on day 13 by nominal D-4F dose
and gender. D-4F was given at hour 0. As expected, exposure to higher nominal doses of D-4F resulted in greater plasma D-4F levels.
Concentrations also differed between men and women, the latter achieving higher D-4F levels, especially at the higher doses. Among
women, the 500 mg group is censored, having excluded a woman with extraordinarily high D-4F levels, thus underestimating the full effect
of 500 mg on women. (b) The area under the curve (AUC) was determined over 8 h on day 13, and is again presented by nominal D-4F
dose and gender. Here, it was practical to present the women exposed to 500 mg as censored and uncensored bars for comparison.
Consistent with a, women had higher D-4F AUC. Because the uncensored analysis compresses the other bars, the inset presents the
100 mg and 300 mg groups separately for clarity. (c) We modeled the dose/response curve between effective D-4F oral dose and plasma
exposure as D-4F AUC. The optimal fit was obtained by effective D-4F dose in mg D-4F per kg ideal body mass, rather than the nominal
D-4F dose (P < 0.0001; R2 = 0.78). See Supplementary Table S3 for details. The dose/response relationship was greater than linear with
no evidence of a plateau at the upper end of the dosing range; as such, an exponential function provided a better fit than a straight-line
function. The blue markers indicate men and the red indicate women. CHD, coronary heart disease; CI, confidence interval.

studies, and larger fixed doses in studies reducing D-4F to
practice.
We also evaluated models including plasma D-4F exposure (Supplementary Table S4, models 5/6). Unlike oral
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dose, modeling HII by D-4F levels revealed plasma exposure was profoundly weaker and, indeed, unrelated (model
5; P = 0.3; Supplementary Figure S3). Tellingly, when oral
dose was added to the model with D-4F exposure, oral dose
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Table 4 HDL inflammatory index pharmacodynamics: postdose time course over 8 h on day 13
Parameter

Sucrose Placebo

100 mg D-4F + Sucrose

300 mg D-4F + Sucrose

500 mg D-4F + Sucrose

1.25 UR (1.09–1.41)

1.21 UR (1.05–1.37)

1.35 UR (1.19–1.51)

1.22 UR (1.05–1.39)

0 h postdose
HII
2 h postdose
HII

0.82 UR (0.66–0.98)

0.99 UR (0.83–1.15)

0.79 UR (0.63–0.95)

0.73 UR (0.56–0.90)

Delta-HII

–0.43 UR (–0.25,–0.61)

–0.22 UR (–0.04,–0.39)

–0.56 UR (–0.39,–0.74)

–0.50 UR (–0.31,–0.68)

Percent change

–31.1% (–43.7,–18.6%)

–15.8% (–28.4,–3.2%)

–37.8% (–50.3,–25.2%)

–40.5% (–53.5,–27.5%)

P = 0.0001

P = 0.0153

P = 0.0001

P = 0.0001

+15.3% (–2.6,+33.3%)

–6.7% (–24.6,+11.3%)

–9.4% (–27.6,+8.9%)

P = 0.0936

P = 0.4648

P = 0.3118

Placebo-adjusted percent change

Fast ended and subjects took daily medications, including morning ASCVD-prevention regimen
4 h postdose / 2 h post-ASCVD regimen and breakfast
HII

0.91 UR (0.75–1.07)

1.10 UR (0.94–1.26)

0.71 UR (0.55–0.87)

0.74 UR (0.57–0.91)

Delta-HII

–0.34 UR (–0.17,–0.52)

–0.12 UR (+0.06,–0.29)

–0.64 UR (–0.47,–0.82)

–0.48 UR (–0.30,–0.66)

Percent change

–26.1% (–38.6,–13.5%)

–7.1% (–19.6,+5.5%)

–44.5% (–57.1,–32.0%)

–38.3% (–51.3,–25.3%)

P = 0.0001

P = 0.2714

P = 0.0001

P = 0.0001

+19.0% (+1.0,+36.9%)

–18.5% (–36.4,–0.5%)

–12.2% (–30.5,+6.0%)

P = 0.0386

P = 0.0441

P = 0.1875

Placebo-adjusted percent change
8 h postdose / 4 h post-ASCVD regimen and breakfast
HII

0.86 UR (0.70–1.02)

1.00 UR (0.84–1.16)

0.57 UR (0.41–0.73)

0.63 UR (0.46–0.80)

Delta-HII

–0.39 UR (–0.21,–0.56)

–0.22 UR (–0.04,–0.39)

–0.79 UR (–0.61,–0.96)

–0.59 UR (–0.41,–0.77)

Percent change

–27.9% (–40.5,–15.4%)

–16.6% (–29.2,–4.0%)

–54.7% (–67.2,–42.1%)

–48.5% (–61.5,–35.5%)

P = 0.0001

P = 0.0109

P = 0.0001

P = 0.0001

+11.3% (–6.6,+29.3%)

–26.8% (–44.7,–8.8%)

–20.6% (–38.9,–2.3%)

P = 0.2140

P = 0.0039

P = 0.0276

Placebo-adjusted percent change

ASCVD, atherosclerotic cardiovascular disease; HDL, high-density lipoprotein; HII, high-density lipoprotein inflammatory index; UR, unit ratio, the native units for
HII.
ASCVD Delta-HII is simply the postdose HII minus predose HII on the UR scale. Percent change is Delta-HII/predose HII × 100% on the percent scale. The
placebo-adjusted percent change subtracts the percent change from the placebo group for each group on active D-4F, on the percent scale. Data are presented
as mean (95% confidence interval).

remained highly predictive of HII (model 6; P < 0.0005) with
even less support for any influence by plasma D-4F (P = 0.6).
This implies oral peptide dose is an overwhelmingly dominant
HII predictor, excluding any apparent role for plasma D-4F
exposure.
As a sensitivity analysis, we included data from the two
other human studies, BP-01 and BP-02. Baseline characteristics for BP-01 are provided in Supplementary Table S5,
and BP-02 is described elsewhere.15 This extended the dose
range on the rapid-descent phase (i.e., before the pre-floor
breakpoint), by including 10 mg and 30 mg doses. These
studies also provided more data on 100–500 mg D-4F and
extended the risk profile into the primary prevention realm.
Perhaps most appealing, broadening the analysis added
more women. The expanded analysis affirmed the floored
shape of the dose/response curve (R2 = 0.35/P < 0.0001;
Figure 2d), and, again, those receiving a dose above the
breakpoint had a significantly better drop in HII vs. placebo
(P = 0.005). The depth to the floor was shallower upon including lower-risk subjects. This is intuitive, as healthier subjects
are less apt to have pro-inflammatory HDL at baseline.
Conversely, the deeper floor for high-risk subjects suggests
greater therapeutic opportunity for the sicker population.
Unsurprisingly, HII was the only pharmacodynamic parameter altered by D-4F, and the ancillary lipid or anti-inflammatory
biomarkers remained stable as in the prior study;

therefore, repeated dosing did not lead to emergent changes,
as expected.
DISCUSSION
This is the first multiple-dose study of oral D-4F in humans,
and, encouragingly, chronic daily dosing was generally welltolerated. Overall, the frequency and types of SEs in this
study population were not unexpected, and not even AEs
of severe intensity necessitated D-4F withdrawal. Echoing
our prior single-dose study,15 all subjects in the present
study had elevated baseline HII. Previously, HII significantly
improved 4 h after a single dose of 300 mg, and 2 h after a
single dose of 500 mg vs. placebo.15 Here, we report after 13
consecutive days, doses of 300 mg D-4F significantly lowered HII 4–8 h postdose. HII returns to baseline by 24 h, suggesting prolonged suppression might require multiple daily
dosing or much higher doses. We gave unformulated D-4F,
making no attempt to prolong delivery; doing so might reduce
the dosing interval.
It is important to appreciate the drop in HII from D-4F
occurred in patients who were already on statins and other
ASCVD-preventing medications, indicating an additive effect
rather than an isolated effect. For comparison, Ansell et al.11
also studied a population with CHD/equivalent risk with
pro-inflammatory HII (1.38 UR), except their subjects were
www.cts-journal.com
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Figure 2 (a) The time course for the change in high-density lipoprotein (HDL) inflammatory index (HII) is presented over 8 h on day 13 as
mean and SEM. Subjects drank D-4F in a sucrose solution at hour 0, and withheld their usual daily medications and fasted for at least
2 h postdose. By 2 h postdose, HII was uniformly lower than baseline in all groups (i.e., no D-4F group varied from the placebo group).
Then subjects ate breakfast and took their usual medications, including their usual regimen to prevent atherosclerotic vascular disease
(ASCVD). Thereafter, higher D-4F groups ultimately diverged from the placebo group. Among those receiving 300 mg or more of D-4F,
the HII dropped below that of the placebo group at either 4 h or 8 h postdose. In contrast, those receiving 100 mg of D-4F were no
better than placebo, and were even worse than placebo at one point (hour 4). The range for the effective dose of D-4F is provided as
mg D-4F/ideal body mass (mg/kg). The data from this panel are also shown in Table 4 using various scales, including the absolute scale
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in unit ratio (UR), change from baseline in UR, and the raw and placebo-adjusted percent change. (b) The time course curves for each
subject on day 13 are presented as HII incremental area under the curve (incAUC 0–8 h), as described in the Methods and illustrated
in Supplementary Figure S1. Briefly, the incAUC is the difference between the postdose HII absolute AUC (absAUC) and the predose
baseline projected over 8 h (T0 × 8 h). Because the HII typically drops below baseline, the difference (HII absAUC — T0 × 8 h) results in a
negative number. A negative HII incAUC is interpreted as HII suppression over 8 h compared to predose HII, that is, a less inflammatory HII.
Conversely, a positive HII incAUC would have been interpreted as HII potentiation, that is, a more inflammatory HII. Each subject’s incAUC
was calculated from HII on its native/absolute scale, the UR; thus, the units for the incAUC are UR*hour over 8 h. We then calculated
the mean and SEM of all the individual incAUCs for each group, and present the aggregated HII suppression as incAUC by group. The
mean and SEM for the group receiving placebo + ASCVD medications is presented as a horizontal band, and groups receiving D-4F +
ASCVD medications are presented as bars with mean and SEM. The test for trend by nominal dose supported an inverse relationship
(rho –0.32; P = 0.01), suggesting higher D-4F doses are generally more apt to render HII less inflammatory than lower doses. That said,
the 300 mg and 500 mg doses were not significantly different from each other, suggesting a threshold dose/response relationship rather
than a linear relationship. Were a linear relationship operative at the highest dose, one would instead expect the 500 mg dose to vary from
the 300 mg, and in the direction of greater HII suppression. Instead, they seem to provide similar HII suppression, more consistent with a
flat dose/response relationship. For comparison, the insets within c and d pool the 300 mg and 500 mg dose groups. (c) Dose/response
curve between effective D-4F dose and HII incAUC on day 13 as described in b. The effective D-4F dose is the nominal D-4F dose in mg
per kg ideal body mass (IBM; mg/kg). As effective dose increased, the HII incAUC declined, consistent with more anti-inflammatory HDL.
This continued until an effective dose of 3.5 mg/kg. At higher effective doses, the dose-response curve hit a floor, beyond which higher
doses did not lower HII incAUC further, as suggested by the similar HII suppression from the 300 mg and 500 mg dose groups in b. A
flat/floored dose/response relationship suggests there is a limit to which D-4F can render HII more anti-inflammatory rather than continued
linear dose responsiveness. For more details on the curve analysis, see Supplementary Table S4. The inset compares HII suppression
as incAUC below and above the threshold. Below 3.5 mg/kg, the HII incAUC was numerically worse than placebo, but not significantly
so, whereas above 3.5 mg/kg, the HII suppression was significantly improved beyond placebo (P = 0.0287). (d) This panel takes the same
approach as c, but expands the dose range by adding two doses in the linear descent portion (10 mg and 30 mg) by combining the day
13 data from c with single-dose human studies of D-4F. Doing so enhances the sample size for the 100 mg, 300 mg, and 500 mg doses,
augments the number of women, and broadens the population by including subjects whose risk does not exceed the threshold for high
ASCVD risk. Again, with increasing effective exposures to D-4F, HII suppression by incAUC improves to a point, but then flattens out to a
floor effect. The data in the inset show that those with effective doses above the threshold have HII that is significantly less inflammatory
than those on placebo (P = 0.0048). CHD, coronary heart disease.

statin-naïve. After 6 weeks, simvastatin 40 mg prompted a
28% drop in HII. In a separate cohort, HII better distinguished
CHD cases from controls than HDL-C. The statin results
provide clinical context for our acute-on-chronic study of
D-4F, in which 300 mg after 8 h lowered HII 55% and
500 mg 49%, compared to a 28% drop in the control group
(Figure 3). Intriguingly, the control group also had a drop in
HII over 8 h that was nearly identical to the magnitude of the
statin benchmark. Indeed, we designed our experiment so
our patients with CHD took their morning ASCVD-preventive
medications during the extended observation period (day
13, 2 h postdose). This likely contributed to the prolonged
(8 h) drop in HII following D-4F or placebo. The improvement
may also involve a diurnal phenomenon or an effect of prolonged fasting or bed rest, as HII also improved 2 h postdose. Although these factors may have initiated the drop in
HII across all groups, we speculate the drop was perpetuated over 8 h by the ASCVD medications taken by all groups.
However, as we cannot parse out the causes for the universal
drop, we can deduce it involves a 28% drop by the end of 8 h
based on the placebo group. Subtracting this effect from the
total drop in HII from D-4F gives an idea of the apparent drop
attributable to D-4F (i.e., the effect D-4F superimposed upon
any cumulative effects of diurnal, fasting, or unknown effects
and ASCVD medications). Thus, 300 mg D-4F prompted a
placebo-adjusted drop in HII of –27% and 500 mg dropped
it –21%. Thus, these doses lower HII by a similar magnitude as simvastatin 40 mg, but more importantly, are additive to chronic statin therapy, because statin use was mandatory in our experiment. Interestingly, adding the statin in the
Ansell et al.11 study lowered HII, but failed to get it “across
the finish line” that is, statins failed to lower HII from a proinflammatory baseline to the anti-inflammatory range of <1.0
UR. In contrast, adding 300–500 mg D-4F to statin lowered

HII to a decisively anti-inflammatory level, around 0.60 UR.
A novel implication is that using both lipid-altering medications together can achieve such a profound drop in HII that
HDL is actually rendered anti-inflammatory compared, which
typically does not happen with statin monotherapy. Beyond
lipid-altering medications, others have shown that diet and
exercise can lower HII 21%,13 and anti-inflammatory medications can lower HII among patients with rheumatoid arthritis
17–18%.14 It would be interesting to determine whether diet
and aerobic exercise are additive to lowered HII from D-4F,
as exercise alters apoA-I and HDL function, opening up the
possibility of overlapping mechanisms. If so, perhaps D-4F
could be used as a gymnomimetic to mimic or augment a
benefit of exercise when activity is limited.22
The dose/response relationship between nominal D-4F
dose and HII did not seem linear, motiving exploratory analyses to better define the relationship. As in the single-dose
study,15 the HII response seemed dose-responsive to a
point. Specifically, 3.5 mg/IBM orally administered D-4F
significantly lowered HII vs. placebo. When data from healthier subjects were included, the floor was shallower/closer
to baseline, suggesting D-4F suppresses HII better when
starting at a more pro-inflammatory baseline (e.g., in sicker
patients). In retrospect, constraining dosing to once-daily
probably limited D-4F’s efficacy. Conversely, multiple daily
dosing or formulating D-4F to extend delivery throughout
the day might influence trough assays. Perhaps this would
deepen the HII floor response further; alternatively, the floor
may indicate there is simply a limit to how much apoA-I or
its mimetics can suppress HDL’s inflammatory properties.
In either case, future studies should broaden daily exposure
(e.g., thrice daily).
Surprisingly, the dose/response relationship for HII was a
function of oral peptide ingestion but not plasma exposure.
www.cts-journal.com
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Figure 3 Arrows represent the change in high-density lipoprotein (HDL) inflammatory index (HII) from various interventions, where the
arrow base is that population’s aggregated mean HII pre-intervention, expressed as a unit ratio (UR). The arrow tip is that population’s
mean HII following the intervention. An individual HII above 1.0 UR is pro-inflammatory, indicating monocyte chemotactic activity (MCA)
increased when HDL was added to low-density lipoprotein in that individual’s culture. Conversely, an HII below 1.0 R is anti-inflammatory,
that is, MCA decreased upon adding HDL. The statins represent a benchmark as a lipid-altering drug that can lower HII. Ansell et al.11
showed that adding simvastatin 40 mg daily to a population of statin-naïve patients with coronary heart disease (CHD) or equivalent risk
can lower HII as much as 28%. Thus, on average, the statin rendered patients with CHD HIIs less inflammatory than they were before
starting that statin. Unfortunately, this was not sufficient to render most patients’ HDL anti-inflammatory, as the mean HII remained >1.0
UR, albeit, much closer to 1.0 UR than before. The inability of the statin to convert most patients with CHD HII from pro-inflammatory to
anti-inflammatory motivates other approaches that could be added to statins, including D-4F. Hence, as a complementary lipid-altering
approach, we present the results of superimposing 300–500 mg D-4F upon chronic statin therapy in our population with CHD or equivalent
risk, at 8 h post D-4F on day 13. We use a pair of arrows to depict the D-4F results to distinguish the “placebo-corrected” drop associated
with D-4F as the lower/yellow arrows, and the drop in the control group in the upper/pink arrows. This is an important distinction, as, on
average, both groups experienced a drop from baseline. Importantly, patients took their usual preventive medications for atherosclerotic
cardiovascular disease (ASCVD) at 2 h. Those who added the ASCVD medications to placebo had a 28% drop in HII. Those on 300 mg
D-4F + ASCVD medications had a 55% drop in HII, and after subtracting the 28% from the control group, a net drop of 27% attributable to
D-4F beyond that of the control group. Likewise, those on 500 mg D-4F + ASCVD medications had a 49% drop in HII, and after subtracting
the 28% drop from the control group, a net drop of 21% drop attributable to D-4F. For both D-4F doses shown, superimposing D-4F
upon the usual ASCVD regimen was sufficiently additive to robustly render the vast majority of our high-risk patients’ HII anti-inflammatory.
Indeed, the average HII was suppressed to 0.57 UR on 300 mg and 0.63 UR on 500 mg. For comparison, others have shown interventions
outside of lipid-altering medications can lower HII. Roberts et al.13 demonstrated HII suppression among overweight/obese men with CHD
risk factors from a high-fiber/low-fat diet and aerobic exercise, which lowered HII 21%. Charles-Schoeman et al.14 demonstrated several
intensive anti-inflammatory regimens lowered HII 17–18% among patients with rheumatoid arthritis: methotrexate monotherapy (MTX),
MTX with etanercept (ETN), and triple therapy with MTX, sulfasalazine (SSZ), and hydroxychloroquine (HCQ).

This would not be expected of a peptide whose efficacy
depends on delivery to plasma or downstream; rather, this
evokes a presystemic mechanism, which nicely accords
with mounting preclinical evidence discussed below. Thus,
a novel aspect of the current report is the dose/response
analysis supporting the concept that D-4F peptide need not
reach the plasma to influence HDL, provided enteric delivery
is sufficient. This is noteworthy as most orally administered
peptides, including D-4F, achieve very low plasma delivery,
tempering enthusiasm for development. Conversely, if it
altered HDL before even reaching plasma, limited plasma
exposure might not present an obstacle for D-4F to improve
this aspect of HDL function, thus encouraging the development of oral apoA-I mimetic peptides. Patients with
CHD or equivalent risk often have pro-inflammatory HDL
by HII,11 which also typifies conditions predisposing to
CHD events: type 2 diabetes,18 chronic kidney disease,19
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infection,23,24 and postsurgery.25 Pro-inflammatory HDL
also accompanies advanced heart failure26 and severe pulmonary hypertension.27 The anatomy of the small intestine
villus requires lipoproteins (including HDL) synthesized in the
enterocytes to pass through the lamina propria of the villus
to enter lymphatic or capillary circulation, both accessed in
the lamina propria. A plethora of immune cells surrounds
the lymphatics and capillary tuft in the lamina propria.
Chattopadhyay et al.28 fed mice a Western diet, and found
oxidized phospholipids were formed in the lamina propria
and provoked an intense inflammatory response in this area
of the villus. It is known that HDL assembled in areas of
inflammation loses its anti-inflammatory properties.29 Chattopadhyay et al.28 also demonstrated adding to the Western
diet an apoA-I mimetic peptide resembling 4F, Tg6F,
dramatically suppressed oxidized phospholipid production and the related intense inflammatory response in the
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villus. At least 30% of circulating HDL originates in the
small intestine.30 It is entirely possible that much of the
dysfunctional HDL in our patients originated in their small
intestine, and oral D-4F acted similarly to Tg6F, improving HII
by reducing the inflammatory response in the villi of the small
intestine. If so, the proportion of HDL originating from the
small intestine might dictate the maximal benefit achieved
by delivering D-4F peptide to the villus. Unless D-4F stimulates enteric HDL synthesis, even if it rendered enteric HDL
completely anti-inflammatory, because 70% of total HDL
originates outside the gut, there would be a hard limit to the
maximal benefit of D-4F. If so, adding D-4F would improve
HII up to a point, after which higher D-4F doses would not
improve HII appreciably. We speculate this could cause the
floored dose response we saw, and simultaneously explain
why plasma exposure seems irrelevant to efficacy. This
hypothesis needs to be directly tested in future research.
Regardless of how, when, or where HDL becomes proinflammatory, D-4F has emerged as a potent tool to suppress HII. Indeed, D-4F reversed pro-inflammatory HDL
from patients with CHD when added to patients’ plasma
in vitro,31 dramatically decreased atherosclerosis in mice8
and rabbits,32 and with statin9 regressed atherosclerosis in
mice. D-4F was also anti-inflammatory in a murine influenza
model,16 reduced murine cerebral33 and renal34 arteriolar inflammation, and improved vascular function, reduced
angiostatin, and decreased oxidative stress to improve
angiogenic potential in the heart of tight-skin mice.35 Our
protocol required patients to take statins, so the drop in
HII may not translate to statin-averse/statin-intolerant populations. At this point, preclinical evidence suggests apoAI mimetics improve atherosclerosis. However, we made no
attempt to measure atherosclerosis in this study, so our data
do not inform the larger question of whether D-4F might
prove atheroprotective in humans. That said, given acceptable safety/tolerability and the facility of chronic daily dosing,
the theoretical potential for benefit favors further development, especially because oral peptide dosing has not proven
a barrier to improving HII.
As expected, the ancillary pharmacodynamic parameters
and clinical lipids did not change with D-4F. This may reflect
wide variations in concomitant ASCVD therapies (e.g., beta
blockers, nitrates, angiotensin converting enzyme inhibitors,
and aspirin). The unknown effect of medications on the other
pharmacodynamic parameters may have further confounded
the results. Thus, the decision to not standardize concomitant CHD or even diabetes mellitus medications may have
limited the ability to detect changes in CHD biomarkers
beyond HII.
D-4F pharmacology
After 13 consecutive daily doses, oral D-4F yielded low
plasma levels (i.e., nanograms/mL of peptide). D-4F was
rapidly absorbed (Tmax 1–2 h across all doses), but minimally
so. One woman on 500 mg had plasma concentrations 10fold above her cohorts at several time points. The remaining women achieved much higher plasma D-4F levels than
men, especially on 500 mg. This may reflect higher effective
doses we gave women. Indeed, this study identified major
differences in apparent D-4F absorption between men and

women. As this was not anticipated, we made no attempt
to enroll similar numbers of women as men. Because the
finding is based on a fairly small number of women, it may
not generalize to all women, especially heavier women. Furthermore, an obvious shortcoming is that censoring overly
influential but valid data post hoc biases our pharmacokinetic results toward underestimating plasma D-4F exposure, and this is especially true of our data for women. The
dose/response analyses were exploratory, and should be
considered hypothesis-generating. To test gender effects,
future studies should enroll more women and dose D-4F by
IBM. Pharmacokinetics support future studies dosing D-4F
3.5 mg/IBM to suppress HII, which would probably require
doses over 500 mg, based on TIs.
Do plasma pharmacokinetics mediate HDL
anti-inflammatory benefits?
When this study was designed, it was presumed D-4F altered
HDL function upon systemic exposure, which also motivated
subsequent studies involving i.v. 4F dosing. Remarkably,
plasma D-4F exposure did not influence the dose/response
between D-4F dose and HII, raising a serious challenge to the
presumption that i.v. exposure is even helpful. If plasma levels had mediated the dose/response, this should dominate
the dose/response model at the expense of the dose administered. On the contrary, plasma D-4F seemed completely
disconnected from HII suppression, not just in the present
study, but also across all three human studies undertaken,
justifying skepticism that systemic exposure is necessary or
even helpful to improve HII. It is conceivable that the disconnect between plasma levels and altered HDL function could
result from a major loss of D-4F before reaching plasma. Even
with first-pass loss, one might expect even a weak relationship between plasma exposure and improved HDL function,
but there was no hint of such. On the other hand, emerging
preclinical evidence strongly supports a primarily intestinal
site of action, as discussed below, which may explain why
systemic exposure is uninformative. Thus, whereas a firstpass effect is conceivable, we think a presystemic site of
action is better supported by current evidence.
L-4F differs from D-4F in being composed of L-amino
acids. Injecting patients with CVD with s.c. or i.v. L-4F
at 0.03–1.1 mg/kg yielded Cmax of 324–10,062 ng/mL.36
Despite such prodigious plasma concentrations, L-4F failed
to improve their HII.36 In contrast, orally administered D4F peptide yielded profoundly lower Cmax , only 2.25–67.3
ng/mL, yet significantly suppressed HII at doses 3.5 mg/kg.
One possible explanation is that L-4F and D-4F are not comparable. We doubt this, as their efficacy was indistinguishable in vivo32 when administered s.c. More likely, the initial
premise that efficacy would require achieving a critical mass
in plasma was misguided.
Where is the site of action for D-4F to render HDL less
inflammatory?
If orally dosed D-4F peptide does not require plasma exposure to suppress HII, then where does it act? Navab et al.37
gave apoE-null mice 45 mg/kg D-4F orally or s.c. Plasma
levels were 1,000-fold higher after s.c. vs. oral administration. Regardless of route, 4.5–45 mg/kg suppressed HII
www.cts-journal.com
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and serum amyloid A, whereas lower doses did not. Moreover, 45 mg/kg by either route reduced aortic atherosclerosis 50% in apoE-null mice on a Western diet. Tellingly, for
each dose, fecal D-4F recovery was similar whether the peptide was administered orally or s.c.,37 further affirming D-4F
dose rather than plasma exposure drives efficacy.
This study implicated the intestine as a major site of action
for the peptide; moreover, this was regardless of administration route.37 Navab et al.38 affirmed this by feeding a Western diet to LDLR-null mice, and dosing D-4F orally or s.c.
at 45 mg/kg/day. After s.c. injection, plasma D-4F was 298fold higher than after the same oral dose, and hepatic levels
were 96-fold higher after injection compared to oral administration. However, small intestine levels only varied 1.66 ±
0.33-fold.38 Arachidonic and linoleic acid metabolites were
suppressed in the intestine, liver, and hepatic bile, irrespective of administration route, as was plasma serum amyloid
A.38 Thus, even though systemic and oral dosing led to major
differences in hepatic and plasma exposure, similar intestinal
concentrations resulted in similar efficacy.
Zhao et al.39 tested an apoA-I mimetic peptide with no
sequence homology to D-4F, in LDLR-null mice on a Western diet. Dosing 40 mg/kg/day by i.p. injection, plasma levels were 22 ± 3 μM and whole-aorta atherosclerosis was
reduced 55%, and aortic-sinus atherosclerosis was reduced
by 61%. After administering 75 mg/kg/day of the peptide
orally, none was detectable in plasma, and yet, whole-aorta
atherosclerosis decreased 58% and aortic-sinus atherosclerosis decreased 71%,39 elegantly demonstrating plasma
exposure of this apoA-I mimetic peptide was dissociated
from its ability to remediate atherosclerosis. Thus, animal
studies imply it does not matter whether an apoA-I mimetic
is given by injection or infusion or orally, so long as the enterocytes receive a certain threshold.
Meriwether et al.40 recently showed i.v. administration of
both D-4F and L-4F in mice selectively targeted the small
intestine and the peptides were transported into the intestinal lumen. Intriguingly, the 4F peptide altered transintestinal
cholesterol efflux, one of the major processes for clearing
excess cholesterol from the body. Why did s.c. or i.v. L-4F
not prove anti-inflammatory?36 The simplest answer would
be that the doses were too low to achieve the requisite enteric
exposure. Supporting this hypothesis, we found HII was most
consistently improved when 3.5 mg/kg IBM oral D-4F peptide was given, whereas the highest L-4F dose in the studies
by Watson et al.36 was 1.1 mg/kg and only a few subjects
received this dose; most received 0.43 mg/kg.
Based on the preclinical evidence, our mechanistic
hypothesis is that apoA-I mimetics require sufficient enteric
delivery to prevent villus inflammation and perhaps drive
transintestinal cholesterol efflux. This could be achieved by
an oral dose (e.g., 3.5 mg/IBM) or driving plasma systemic
exposure so high it manages to reach the enterocyte from
the other side. Logistically, oral dosing would be preferable
to patients and its lower doses easier to supply. Regarding
HII specifically, as before, D-4F may dampen inflammation in
the villi, thereby reducing the formation of dysfunctional HDL
as the lipoprotein transits from the site of synthesis (the enterocyte) through the site of inflammation (the lamina propria of
the villus) on its way into the circulation without D-4F directly
Clinical and Translational Science

associating with HDL or even being absorbed. Alternatively,
any D-4F that does get absorbed may integrate with nascent
HDL as it is assembled in the peri-enterocytic space.
Whither ApoA-I mimetics?
In an editorial accompanying the report by Zhao et al.,39
Wool, Reardon, and Getz41 offered that this body of work
has “raised the exciting possibility of a future orally available agent targeted at improving HDL function, likely through
a gut-mediated mechanism of action.” We believe the data
from the current paper add to the hope that such an agent
can be developed, with the ultimate goal of developing a new
approach to limit atherosclerosis.
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